Home » Topics » Disease categories and therapies » Neurology/psychiatric

Neurology/psychiatric
RSS

TNF research findings

July 12, 1996

Muscarinic receptor ligand selected for further study

July 12, 1996

First demonstration of cellular mechanism of human oral tolerance

July 12, 1996

First approval of SmithKline Beecham's ReQuip in U.K.

July 12, 1996

Lundbeck's Serdolect reaches first market

July 12, 1996

Pharmacia & Upjohn's dopamine D4 receptor ligands

July 12, 1996

Potent, selective mGluR2 agonist from Lilly

July 12, 1996

Potential CNS disorders treatment from Janssen

July 12, 1996

Melatonin effective for jet lag/shift lag

July 12, 1996

Lilly describes heterocyclic tachykinin antagonists

July 12, 1996

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Feb. 14, 2025.
European VCs optimistic for med-tech exit opportunities in 2025
BioWorld MedTech
To say that European investors are optimistic about the outlook for the med-tech sector in 2025 is an understatement. A couple of companies are already listed on...
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for February 14, 2025
European VCs bullish on med-tech investments in 2025
BioWorld MedTech
European companies looking for capital should find the fundraising environment more favorable in 2025. Private med-tech financings in January totaled about $2...
Kura/Kyowa Kirin’s ziftomenib hits phase II endpoints in AML
BioWorld
Kura Oncology Inc. and Kyowa Kirin Co. Ltd.’s selective oral menin inhibitor, ziftomenib, met the primary endpoints in the phase II registrational Komet-001 trial...